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Background: The systemic inflammatory response has been postulated as having prognostic significance in a wide
range of different cancer types. We aimed to assess the prognostic role of inflammatory markers on survival in HIV-
infected patients with Non-Hodgkin Lymphoma (NHL), and to compute a prognostic score based on inflammatory
biomarkers.
Methods: We evaluated data on HIV patients with NLH diagnosis between 1998 and 2012 in a HIV Italian Cohort.
Using Cox proportional regression model, we assessed the prognostic role of Neutrophil-Lymphocyte Ratio (NLR),
Platelet-Lymphocyte Ratio (PLR), Glasgow Prognostic Score (GPS), modified Glasgow Prognostic Score (mGPS),
Prognostic Index (PI), and Prognostic Nutritional Index (PNI). We also computed a risk score equation, assigning
patients to a derivation and a validation sample. The area under the curve (AUC) was use to evaluate the predictive
ability of this score.
Results: 215 non-Hodgkin lymphoma cases (80.0% males) with a mean age of 43.2 years were included. Deaths
were observed in 98 (45.6%) patients during a median follow up of 5 years. GPS, mGPS, PI and PNI were independently
associated with risk of death. We also computed a mortality risk score which included PNI and occurrence of an AIDS
event within six months from NHL diagnosis. The AUCs were 0.69 (95% CI 0.58 to 0.81) and 0.69 (95% CI 0.57 to 0.81) at
3 and 5 years of the follow-up, respectively.
Conclusions: GPS, mGPS, PI and PNI are independent prognostic factors for survival of HIV patients with NHL.
Keywords: Inflammatory markers, Prognostic score, HIV, Non-Hodgkin lymphomaIntroduction
Non-Hodgkin Lymphoma (NHL) is one of the most
common cancer and cause of death among HIV-infected
patients [1-3]. Overall survival is poor and more than
half subjects die within five years from NHL diagnosis,
although it has improved after the introduction of the
combined Antiretroviral Therapy (cART) [2-9].
The International Prognostic Index (IPI) was devel-
oped at the beginning of 1990s by the International
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NHL treated with doxorubicin-containing chemotherapy
in the general population [10]. The IPI categorizes pa-
tients into low, intermediate and high risk groups based
on the baseline characteristics including age, Eastern
Cooperative Oncology Group performance status, Lac-
tate Dehydrogenase (LDH) level, Ann Arbor stage, and
extranodal involvement. The IPI has also been demon-
strated prognostic for lymphomas associated with HIV
infection [4].
Tumor microenvironment and inflammatory response
have an important role at different stages of tumor de-
velopment, including initiation, promotion, malignant
conversion, invasion and metastasis [11]. Recent studiesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Inflammation-based prognostic variables
Variables Criteria Score
GPS C-Reactive Protein ≤1.0 mg/dl and
albumin ≥3.5 g/dl
0
C-Reactive Protein >1.0 mg/dl and
albumin ≥3.5 g/dl
1
C-Reactive Protein ≤1.0 mg/dl and
albumin <3.5 g/dl
C-Reactive Protein >1.0 mg/dl and
albumin <3.5 g/dl
2
mGPS C-Reactive Protein ≤1.0 mg/dl 0
C-Reactive Protein >1.0 mg/dl and
albumin ≥3.5 g/dl
1
C-Reactive Protein >1.0 mg/dl and
albumin <3.5 g/dl
2
NLR neutrophil coun/lymphocyte count <1/3 0
neutrophil count/lymphocyte count 3-5/1 1
neutrophil count/lymphocyte count ≥3/1 2
PLR platelet count/lymphocyte count <150/1 0
platelet count/lymphocyte count 150– 300/1 1
platelet count/lymphocyte count >300/1 2
PI C-Reactive Protein ≤1 mg/dl and white
blood cell count ≤11,000/μl
0
C-Reactive Protein ≤1 mg/dl and white
blood cell count >11,000/μl
1
C-Reactive Protein >1 mg/dl and white
blood cell count ≤11,000/μl
C-Reactive Protein >1 mg/dl and white
blood cell count >11,000/μl
2
PNI albumin (g/dl) × 10 + 0.005 × total 0
lymphocyte count (/μl) ≥45
albumin (g/dl) × 10 + 0.005 × total 1
lymphocyte count (/μl) <45
Abbreviations: GPS Glasgow Prognostic Score, mGPS modified Glasgow
Prognostic Score, NLR Neutrophil/Lymphocyte Ratio, PLR Platelet/Lymphocyte
Ratio, PI Prognostic Index, PNI Prognostic Nutritional Index.
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temic inflammation, i.e. C-Reactive Protein (CRP), white
cell, neutrophil and platelet count, and hypoalbuminemia
are predictors of survival in patients with primary solid
cancers [12]. Various combinations of these factors have
been used to derive inflammation-based scores to predict
survival of subjects with solid cancers [13-16], such as
Glasgow Prognostic Score (GPS), Neutrophil/Lymphocyte
Ratio (NLR) and Platelet/Lymphocyte Ratio (PLR).
Few studies have investigated the association between
these inflammatory scores and survival in patients with
NHL [17-19], none of which in HIV-infected patients,
so far.
The aims of this study were: (i) to evaluate the prog-
nostic role of inflammatory markers on survival in HIV-
infected patients with NHL and, (ii) to compute a prog-
nostic score based on demographical and clinical vari-
ables and inflammatory biomarkers.
Methods
The Italian MASTER cohort is a hospital-based multi-
center, open, dynamic cohort established in the mid-
1990s with retrospective patients’ enrolment since 1986.
At present, the cohort includes about 24 500 HIV-
infected subjects, aged 18 years or older, at eight Infec-
tious Diseases Units throughout Italy. In this work we
included HIV-infected patients with a first NHL diagno-
sis between January 1998 and December 2012. The study
design and cancer collection data have been described
previously [1].
We retrieved gender, age, country of origin, HIV ex-
posure risk, date of enrolment in the cohort, Hepatitis B
Virus (HBV) or/and Hepatitis C Virus (HCV) co-
infection and cART at cancer diagnosis from the MAS-
TER electronic database. The following parameters,
measured within 6 months from the diagnosis of NHL,
were also retrieved: AIDS event occurrence, HIV-RNA,
CD4 cell count, CD8 cell count, CRP, albumin, white
blood cell, neutrophil, lymphocyte and platelet counts.
The inflammatory based prognostic variables GPS,
modified Glasgow Prognostic Score (mGPS), NLR, PLR,
Prognostic Index (PI), and Prognostic Nutritional Index
(PNI) were defined as shown in Table 1.
The study was conducted in accordance with the
guidelines of the Declaration of Helsinki and the princi-
ples of Good Clinical Practice. Informed consent was
obtained according to the standards of the local ethics
committees.
Statistical analysis
The primary outcome of this study was all-cause mortal-
ity. The cumulative risk of death was determined from
the data of NHL diagnosis to the end of the observation
period. The censor date for survival analysis was 31stDecember 2012. The observation period ended either on
31st December 2012, or at last follow-up visit or death,
whichever occurred first. Patients lost to follow-up con-
tributed to the time at risk until last visit.
At first, the associations of each prognostic variable
with all-cause mortality were tested by univariate and
multivariate analysis using Cox proportional hazard
models. Gender, age at cancer diagnosis, intravenous
drug use, AIDS defining event, HBV and/or HCV co-
infection, cART, CD4 cell count, HIV-RNA undetectable
were included as covariates. The results were expressed
as Hazards Ratios (HRs), their 95% Confidence Intervals
(95% CIs), and p-values according to Wald test. Due a
few missing data in GPS, mGPS, PLR, PI, and PNI, the
Cox proportional hazard regression models were ad-
justed by stabilized inverse probability weights with
Table 2 Demographical and clinical features at
non-Hodgkin lymphoma diagnosis
Variables Categories n (%)
Total 215
Gender Male 172 (80.0)
Age (years) <35 31 (14.4)
35-49 136 (63.3)
≥50 48 (22.3)
Mean (SD) 43.2 (9.0)
Period of Diagnosis 1998-2002 71 (33.0)
2003-2007 88 (40.9)
2008-2012 56 (26.1)
IDU Yes 96 (42.8)
Migrants Yes 28 (8.7)
Previous AIDS defining event Yes 81 (37.7)
HBV or/and HCV co-infection Yes 111 (51.6)
cART Yes 172 (80.0)
CD4 cell count, cell/mm3 <200 104 (54.2)
≥200 88 (45.8)
Mean (SD) 275.9 (235.3)
CD4/CD8 Ratio <1 158 (89.3)
≥1 19 (10.7)
Mean (SD) 0.46 (0.50)
HIV-RNA, copies/mL Undetectable 49 (26.1)
Positive 139 (73.9)
Mean (SD)* 113208.8 ( 310601.3)




Abbreviations: SD Standard Deviation, IDU Intravenous Drug Use, HBV Hepatitis B
Virus, HCV Hepatitis C Virus, cART combined Antiretroviral Therapy, *In subjects
with positive HIV-RNA.
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at random [20]. In order to compare the fitness of the
model with and without the inflammatory variables, we
used the log-likelihood ratio test.
The Area Under the Receiver Operating Characteristic
(ROC) Curve (AUC) was used to assess the predictive
accuracy of each prognostic variable. As sensitivity ana-
lyses, we assessed the consistency of the prognostic role
of inflammatory variables in subjects who underwent
cART at NHL diagnosis.
Non-linear relationships between continuous prognos-
tic variables and risk of death were assessed by Cox re-
gression models with spline terms of the prognostic
variables [21]. We used the Akaike’s information criter-
ion [22] to assess fitting of models with linear and non-
linear terms and to choose the number of spline knots.
Subsequently, we derived a risk score of mortality on
the basis of the inflammatory, demographic and clinical
variables. To this end, the patients were randomly di-
vided into two subgroups by split-sample technique: (i)
derivation subgroup including 70% of subjects, and (ii)
validation subgroup, including 30% of subjects. In the
derivation sample, a Cox proportional regression model
was used to evaluate the association between baseline
factors and risk of death, using a cut-off of minimal 10
events per variable for first selection of variables. Gen-
der, age at cancer diagnosis, intravenous drug use, AIDS
defining event, HBV and/or HCV co-infection, cART,
CD4 cell count, HIV-RNA undetectable and PNI were
included. Bootstrapping with 1000 replications was per-
formed to check the stability of variables included in the
final models. Linear prediction equations, representing
the risk scores, were derived from the final model. For
visualization purposes, three risk groups were created
according to tertiles of the risk scores distribution in the
derivation sample. Cumulative incidence rates of mortal-
ity among these three groups were compared by the
Kaplan–Meier methods and tested with the log-rank test
for trend in the derivation sample. In the derivation and
the validation sample the AUC was used to assess the
predictive accuracy of the risk scores.
The selection of variables for fitting the most parsimo-
nious models was performed using a backward stepwise
procedure, with p = 0.20 for retaining each variable in
the model. A graphical check on each regressor did not
detect major departures from the proportional hazard
assumption of the model.
All the statistical tests were two-sided, assumed a level
of significance of 0.05 and were performed using Stata
version 12.0 (StataCorp, College Station, TX, USA).
Results
A total of 215 non-Hodgkin lymphoma cases were in-
cluded. They had a mean age of 43.2 years at time ofNHL diagnosis (Standard Deviation, SD = 9.0) and most
of them were males (80.0%). The characteristics of the
patient population at NHL diagnosis are shown in
Table 2. Most of them were assuming cART and plas-
matic HIV-RNA was positive (>37 cp/ml). More than
half patients had severe immunodeficiency with CD4 cell
count less than <200 cells/mm3.
After a median follow up of 2 years (ranging from
2 days to 13.9 years), 18 patients (8.4%) were lost and 98
(45.6%) died. The median survival was 9.3 years. At 1, 3
and 5 years, cumulative risk of death was 34.1%, 44.3%
and 45.7%, respectively.
Prognostic role of inflammation-based prognostic
variables
Table 3 describes the distribution of inflammatory
markers and the association between each of them and
risk of death using Cox regression models. Median time
Table 3 Univariate and multivariate Cox regression models for each inflammatory prognostic variable
Variables Category$ Univariate model Multivariate model
n (%)# n HR (95% CI) P value n HR (95% CI)π P value
GPS* 0 20 (25.3) 79 Ref 65 Ref
1 42 (53.2) 1.82 (0.49-6.69) NS 1.91 (0.45-7.65) NS
2 17 (21.5) 4.39 (1.19-16.2) 0.026 4.78 (1.15-19.77) 0.031
Available 79 (36.7)
mGPS* 0 24 (30.4) 79 Ref 65 Ref
1 38 (48.1) 2.01 (0.61-7.00) NS 2.07 (0.61-7.01) NS
2 17 (21.5) 4.46 (1.36-14.6) 0.013 4.35 (1.16-16.36) 0.029
Available 79 (36.7)
NLR 0 129 (67.2) 192 Ref
1 32 (16.7) 1.31 (0.74-2.30) NS
2 31 (16.1) 1.48 (0.84-2.61) NS
Mean (SD) 2.92 (2.79)
Available 192 (89.3)
PLR 0 97 (48.3) 199 Ref
1 67 (33.3) 1.16 (0.71-1.90) NS
2 37 (18.4) 1.58 (0.88-2.84) NS
Mean (SD) 193.7 (135.1)
Available 199 (92.6)
PI* 0 29 (31.9) 91 Ref 77 Ref
1 60 (65.9) 3.33 (1.12-9.93) 0.030 3.25 (1.06-9.94) 0.039
2 2 (2.2) 3.98 (0.86-28.35) NS 11.3 (1.03-124.9) 0.047
Available 91 (42.3)
PNI* 0 54 (39.7) 136 Ref 114 Ref
1 82 (60.3) 2.36 (1.23-4.53) 0.010 2.57 (1.25-5.30) 0.010
Available 136 (63.3)
Abbreviations: HR Hazard Ratio, 95% CI, 95% Confidence Interval, SD Standard Deviation, GPS Glasgow Prognostic Score, mGPS modified Glasgow Prognostic Score,
NLR Neutrophil/Lymphocyte Ratio, PLR Platelet/Lymphocyte Ratio, PI Prognostic Index, PNI Prognostic Nutritional Index, NS Not Statistical Significant (p > 0.05).
#Colum percentage, *Weighted Cox regression models, πModel adjusted for gender, age at diagnosis, intravenous drug user, AIDS defining event, CD4 cell count
and HIV-RNA undetectable. $For prognostic variables classification see Table 1.
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quartile range: 3–53 days).
Score 0 was attributed to the majority of patients for
NLR, while for PI and PNI most subjects were catego-
rized as score 1. About half of patients were scored with
1 for GPS and mGPS, and with 0 for PLR. No associa-
tions were found between prognostic variables and HIV-
RNA copy number in subjects with positive HIV-RNA at
NHL diagnosis. GPS, mGPS, PI and PNI were independ-
ently associated with risk of death using both univariate
and multivariate Cox models. These results were also
confirmed when we limited the analyses to patients
under cART (data not shown).
The likelihood ratio tests for the global fit of the
model, before and after addition of inflammatory vari-
ables to the full model, were significant for GPS, mGPS,
PI and PNI (p < 0.001).Non-linear relationships between NLR, PLR, PNI and
risk of death were evaluated by using multivariate Cox
regression models with a restricted cubic-spline for each
prognostic score (Figure 1). A trend of increasing risk of
death with increasing PNI was observed, although not
statistical significant, whereas no trend with PLR and
NLR was found.
The ROC analysis showed that mGPS, GPS, PNI and
PI had statistically significant discrimination ability, with
AUC ranging from 0.60 to 0.69, with follow-up trun-
cated at both 3 and 5 years (Table 4).
Mortality risk score
Finally, we computed a risk score for death on the basis
of the final Cox model. In the derivation sample (93 sub-
jects with PNI available, 34 of which died), age, occur-
rence of an AIDS defining event within six months from
Figure 1 The relationship between the inflammatory-based prognostic scores considered as continuous (PLR (B), NLR (A) and PNI (C)),
and the hazard ratio of death (HR). The HRs were computed in Cox regression models with cubic spline term for each prognostic score
adjusted for gender, age at diagnosis, intravenous drug use, AIDS defining event, CD4 cell count, cART therapy prescription and HIV-RNA
undetectable. The reference value for each spline term is 3 for NLR, 150 for PLR and 45 for PNI.
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count lower than 200 cells/mm3 and PNI equal to 1
were significantly associated with fatal outcome in uni-
variate Cox regression analysis (Table 5). However, in
multivariate analyses, only occurrence of AIDS defining
event within 6 months from NHL diagnosis and PNI
were independently associated with mortality, also using
bootstrapping technique.
The linear prediction equation for risk of mortality
(Rm) derived from the final Cox model was: Rm = 0. 703
*(occurrence of AIDS defining event within six months
from NHL diagnosis [yes =1/no = 0]) + 0.794* (PNI). TheTable 4 Areas under the ROC curve using various
prognostic variables
Prognostic variables Area under the ROC
curve at 3-year of
follow-up ( 95% CI)
Area under the ROC
curve at 5-years of
follow-up ( 95% CI)
GPS* 0.67 (0.54-0.80) 0.67 (0.54-0.80)
mGPS* 0.69 (0.56-0.82) 0.66 (0.53-0.80)
NLR 0.54 (0.46-0.62) 0.54 (0.47-0.62)
PLR 0.53 (0.45-0.60) 0.54 (0.477-0.62)
PI* 0.63 (0.53-0.73) 0.60 (0.51-0.71)
PNI* 0.65 (0.55-0.74) 0.64 (0.55-0.74)
Abbreviations: ROC Receiver Operating Characteristic, 95% CI 95% Confidence
Interval, GPS Glasgow Prognostic Score, mGPS modified Glasgow Prognostic
Score, NLR Neutrophil/Lymphocyte Ratio, PLR Platelet/Lymphocyte Ratio,
PI Prognostic Index, PNI Prognostic Nutritional Index.
The bold Areas under the ROC curves are those concerning variables resulted
significantly predictive of death.predictive accuracies of this risk score for mortality, as
measured by the AUC, were 0.69 (95% CI 0.58 to 0.81)
and 0.69 (0.57 to 0.81) in derivation sample, and 0.69
(0.49 to 0.90) and 0.73 (0.53 to 0.92) in validation sample
(47 subjects with PNI available, 12 of which died), at 3
and 5 years of follow-up, respectively. As an application
of the score, patients were categorized into three risk
groups: patients without AIDS defining event within six
months from the date of NHL diagnosis and with PNI >
45, patients with AIDS defining event within six months
from the date of NHL diagnosis or with PNI < 45 and
patients with AIDS defining event within six months
from the date of NHL diagnosis and with PNI < 45. Ac-
cording to the 3 risk score categories, cumulative mor-
tality rates were 20.8% (10.4 to 38.9), 31.8% (18.8 to
50.3) and 64.5% (43.3 to 84.8) in the low-, intermediate-
and high-risk group (log rank test p < 0.001) (Figure 2).
As a sensitive analysis, we have also computed a prog-
nostic score including PNI and AIDS events on the
whole cohort, finding AUCs for this score of 67.0 (56.3-
77.6) and 67.9 (57.8-78.1) at 3 and 5 years, respectively.
Discussion
In this study, we investigated the relationship between
some biomarkers of systemic inflammation and overall
survival in HIV-infected patients with NHL for the first
time. We found that some inflammatory-based scores
including serum levels of CRP and albumin (GPS,
mGPS, PI and PNI), but not those based on cellular
Table 5 Cox regression analyses for mortality in the derivation sample
Variable Category Univariate analysis Multivariate analysisπ
n subjects included = 93
HR (95% CI)* P value HR (95% CI)* P value
Gender Male vs Female 1.03 (0.59-1.79) NS
Age (years) 1.02 (1.0-1.05) NS
IDU Yes vs No 1.04 (0.66-1.66) NS
AIDS defining event Yes vs No 1.73 (1.09-2.73) 0.019 2.02 (1.01-4.02) 0.045
HBV or/and HCV co-infection Yes vs No 0.94 (0.60-1.49) NS
cART Yes vs No 0.57 (0.35-0.95) 0.032
CD4 cell count, cell/mm3 <200 vs ≥200 1.79 (1.12-2.88) 0.015
HIV-RNA undetectable Yes vs No 1.52 (0.84-2.73) NS
PNI <45 vs ≥45 2.42 (1.22-4.77) 0.011 2.21 (1.11-4.40) 0.023
Abbreviations: HR Hazard Ratio, 95% CI 95% Confidence Interval, IDU Intravenous Drug Use, HBV Hepatitis B Virus, HCV Hepatitis C Virus, cART combined
Antiretroviral Therapy, PNI Prognostic Nutritional Index, NS Not Statistical Significant (p > 0.05).
*Adjusted for all the variables in the table. πThe mortality risk score based on the regression coefficients of the variables in final model was represented by
0.703*(AIDS defining event [yes =1/no = 0]) + 0.794 * (PNI) [AIDS defining event within six months from NHL diagnosis].
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an independent prognostic value for risk of death. We
also computed a mortality risk score including PNI and
occurring of an AIDS event within six months from
NHL diagnosis, which showed a rather fair predictive
ability, with an AUC of 0.69 at 3 years of follow-up.
Various prognostic parameters have been used for
NHL, so far. Among them, the IPI is probably the most
commonly used and it has been revised recentlyFigure 2 Cumulative risk of death according to occurrence of
AIDS defining event and PNI. The low-risk group included patients
without AIDS defining event within six months from NHL diagnosis and
with PNI > 45; the intermediate-risk group included patients with AIDS
defining event within six months from data of NHL diagnosis or with
PNI < 45; and the high-risk group included patient with AIDS defining
event within six months from NHL diagnosis and with PNI < 45.[10,23,24]. New inflammatory indexes, based on rou-
tinely examined blood parameters, have been proposed,
including NLR and GPS: NLR has been found useful in
patients with diffuse large B-cell lymphoma at low risk
of death [18], whereas an elevated GPS was associated
with poorer survival in patients with extranodal natural
killer/T-cell lymphoma [19] and in those with diffuse
large cell lymphoma treated with R-CHOP [17].
In HIV-infected patients with NHL, however, also
HIV-infection related factors, such as cART, concurrent
infections and baseline immunosuppression, have been
found to influence prognosis [4,7,25]. However, the stud-
ies carried out so far produced inconsistent results. A
low CD4 cell count at NHL diagnosis found to be an in-
dependent risk factor for death in pre-cART and early
cART eras in two large cohorts [3-5,26], whereas history
of AIDS was associated with worse survival only in the
pre-cART era [4]. A protective effect of cART has been
described [27,28]. Other studies, however, found that
only patient- and lymphoma-, but not HIV-related fac-
tors were predictive of poor outcome in the cART era
[7-9]. For this reason, a composite score for HIV-
infected patients with NHL has been recently developed
which involves both HIV infection factors and the vari-
ables included in IPI [29]. Nevertheless, the IPI is not of
common use for HIV patients, because of lack of some
necessary data, and other inflammatory scores based on
routine data, such as NLR and GPS, may be considered.
In our study, we have included all HIV-infected pa-
tients with NHL independently of histology, Ann Arbor
stage or chemotherapy regimen. The 2-year cumulative
risk of death from NHL diagnosis in our cohort was 45%
[1], slightly lower than the 50-70% value reported in pre-
vious studies on HIV-infected subjects [4,5,26,30]. This
is possibly due to the fact that previous studies included
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early 2000s, when both cART and chemotherapy regi-
mens were not so effective as they are todays.
In these subjects, we found that some indexes includ-
ing serum CRP and albumin (GPS and mGPS, PNI and
PI), as representative of systemic inflammation and nu-
trition status, were independent predictors of survival in
HIV patients with NHL. Therefore, we developed a sim-
ple score which integrates clinical and laboratory vari-
ables for assessing risk of death in HIV-infected patients
with NHL. The score includes one of the HIV-related
variables, i.e. an AIDS defining event occurring within
six months from NHL diagnosis, and one inflammatory
score, the PNI, based on common blood parameters
such as lymphocytes and albumin, which therefore can
be easily applied to any patient with newly diagnosed
NHL. We found that this score had a rather fair predict-
ive ability with an AUC of 0.69 at 3 years of follow-up.
There are several strengths in our study, including a
large sample size, multicenter national cohort and inclu-
sion of patients receiving state of the art lymphoma and
HIV care. This study has some limits, too. First, we
could not analyze the prognostic factors according to
type of NHL, due to lack of power of the study for sub-
group analyses. Second, the derivation and validation
samples used to compute and test the prognostic score
were unbalanced (70% and 30%, respectively). In fact, be-
cause of the relatively small number of NHL cases, we
choose to include more subjects (70%) in the derivation
cohort to get better precision of the estimates. Anyway,
we also computed a prognostic score including PNI and
AIDS events within six months from NHL diagnosis on
the whole cohort, finding an AUC for this score similar to
those computed using validation and derivation cohorts.
Conclusions
In summary, our study extends previous findings which
were focused on solid cancers and shows that some
markers of systemic inflammatory response are associ-
ated with poor outcome also in HIV-infected patients
with NHL.
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